Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.85 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.85 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.85 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.79 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.74 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1980549 | 0.96 | HDAC1 (1.00) | HDAC1HDAC2HDAC8HDAC6ALOX5 | |
| SCHEMBL5020670 | 0.93 | HDAC1 (1.00) | HDAC1HDAC2HDAC8HDAC6ALOX5 | |
| SCHEMBL5020672 | 0.92 | HDAC1 (1.00) | HDAC1HDAC2HDAC8HDAC6ALOX5 | |
| SCHEMBL1847911 | 0.92 | HDAC2 (1.00) | HDAC1HDAC2HDAC8HDAC6ALOX5 | |
| Benzene SCHEMBL28125146 | 0.92 | HDAC2 (1.00) | HDAC1HDAC2HDAC8HDAC6ALOX5 | |
| SCHEMBL5020559 | 0.91 | HDAC1 (0.96) | HDAC1HDAC2HDAC8HDAC6ALOX5 | |
| SCHEMBL5020669 | 0.89 | HDAC1 (0.93) | HDAC1HDAC2HDAC8HDAC6ALOX5 | |
| SCHEMBL8610138 | 0.89 | HDAC1 (1.00) | HDAC1HDAC2HDAC8HDAC6ALOX5 | |
| SCHEMBL22190384 | 0.89 | HDAC1 (1.00) | HDAC1HDAC2HDAC8HDAC6ALOX5 | |
| SCHEMBL5807174 | 0.89 | HDAC1 (1.00) | HDAC1HDAC2HDAC8HDAC6ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796330-B2 | Inhibitors of histone deacetylase and prodrugs thereof | METHYLGENE INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-8796330-B2 | Inhibitors of histone deacetylase and prodrugs thereof | METHYLGENE INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2014-01-23 | — | — | US | disclosed |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2014-01-23 | — | — | US | disclosed |
| EP-2573069-A2 | Inhibitors of histone deacetylase and prodrugs thereof | MethylGene Inc. (CA) | 2013-03-27 | — | — | EP | disclosed |
| US-RE43343-E1 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| US-RE43343-E1 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| WO-2008074132-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-RE39850-E1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | METHYLGENE, INC. (CA) | 2007-09-18 | — | — | US | disclosed |
| US-RE39850-E1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | METHYLGENE, INC. (CA) | 2007-09-18 | — | — | US | disclosed |
| EP-1748046-A2 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2007-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC2 5/4885HDAC8 9/4885 |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC2 5/4885HDAC8 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.